News

Get the latest on BIO's announcements, positions and views on everything from healthcare to biofuels.

Press Releases

BIO Statement on Reintroduction of the PASTEUR Act

WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement on the reintroduction of the bipartisan Pioneering Antimicrobial Subscriptions to End Upsurging Resistance …

Learn more

BIO Statement on Passage of Bipartisan…

WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement.“The passage of the Mikaela Naylon Give Kids a Chance Act is a bipartisan victory for children and…

Learn more

BIO Appoints Joe Franklin, JD, PhD, as Chief…

Washington, D.C. (February 2, 2026) -- The Biotechnology Innovation Organization (BIO) today named Joe Franklin, JD, PhD, as its new chief legal and policy officer. Franklin brings deep expertise in the biomedical sector across law, policy, AI, and…

Learn more

Letters, Testimony, & Comments

Browse All

BIO Comments on Global Benchmark for Efficient…

Learn more

BIO Comments on Guarding U.S. Medicare Against…

Learn more

Letter From BIO President & CEO John F. Crowley…

Dear Mr. Thune, Mr. Schumer, Mr. Johnson, and Mr. Jeffries:As President and CEO of the Biotechnology Innovation Organization (BIO), as a father and entrepreneur whose family is here today because of biotech innovation, and on behalf of the more than…

Learn more

Amicus Briefs

Browse All

BIO Files Amicus Brief in Case Addressing Anti…

BIO filed an amicus brief in the U.S. Court of Appeals for the District of Columbia Circuit, seeking the reversal of a lower court decision that found plaintiff Vertex Pharmaceuticals’ patient assistance program in violation of the Anti-Kickback…

Learn more

BIO Files Amicus Brief in Delaware Supreme Court…

BIO filed an amicus brief in the Supreme Court of the State of Delaware, urging the Court to exclude Plaintiffs’ expert opinion, thereby ensuring that Delaware’s standard for the admission of such evidence remains consistent with the federal …

Learn more

BIO Files Amicus Briefs Supporting the Lawfulness…

On February 10, 2025, BIO filed an amicus brief in the U.S. District Court for the District of Columbia, supporting the lawfulness of plaintiff Eli Lilly's proposed 340B rebate model. The 340B Drug Pricing Program ("340B"), through which Medicaid…

Learn more